Pancreatic progenitor cells derived from human embryonic stem or induced pluripotent stem cells hold tremendous potential for modeling pancreatic development and disease, as well as for regenerative therapies addressing degenerative conditions like diabetes. The ability to direct differentiation of pancreatic progenitor cells to specific endocrine cell types has led researchers to propose human pluripotent stem cells as an unlimited source of insulin-producing beta cells for studying and treating diabetes. In this webinar, Dr. Ray Dunn and Dr. Jamie Trott (A*STAR Institute for Medical Biology, Singapore) present their data on generating pancreatic progenitors and beta cells from diabetic-patient-derived induced pluripotent stem cells.
April 18, 2016
Request Webinar Form
Thank you for your interest in this product.
Please provide us with your contact information and your local representative
will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
. Please contact us
with any questions that you may have. You can unsubscribe or change your email preferences
at any time.